Citations

Clear

3042 citation(s) found for "Kumar, S".

Active surveillance versus stereotactic radiosurgery for Koos grade I and II vestibular schwannoma in patients aged 60 years or older
Ishaque, Mariam , Tos, Salem M., Hajikarimloo, Bardia, Fuentes, Angelica M. , Abou-Al-Shaar, Hussam, Peker, Selcuk, Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj, Schulder, Michael , Tourigny, Jean-Nicolas, Mathieu, D, Hamel, Andréanne, Briggs, Robert G., Yu, Cheng , Zada, Gabriel, Giannotta, S L, Palque, Sarai, Kumar, S Praveen, Kumar, Narendra, Rogowski, Brandon, Shepard, Matthew J., Trifiletti, Daniel M., Dayawansa, Sam, Vasconcellos, Fernando De Nigris, Bernstein, Kenneth , Schnurman, Zane, Alzate, Juan, Kondziolka, Douglas, Sheehan, Jason P., Johnson, Bryan A, Mantziaris, Georgios , Tos, Salem M , Hajikarimloo, Bardia , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Peker, Selçuk , Samancı, Yavuz , Goenka, Anuj , Mathieu, David , Zada, Gabriel , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kaur, Rupinder , Rogowski, Brandon, Johnson, Bryan A., Trifiletti, Daniel M. , Warnick, Ronald E. , Dayawansa, Sam , Mashiach, Elad , Vasconcellos, Fernando De Nigris , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas, Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery | May 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2026.1.jns242756 | PMID 42139729 Get It

OBJECTIVE The aim of this study was to evaluate freedom from tumor progression and clinical outcomes in older adults with small- to medium-sized vestibular schwannoma (VS) managed by observation versus stereotactic radiosurgery (SRS) to better inform optimal management in this patient population. METHODS In this international multicenter study, patients aged ≥ 60 years with Koos grade I or II VS managed by observation or SRS were retrospectively reviewed. Propensity score matching was conducted using patient characteristics, tumor size, and hearing assessments. Outcome measures of freedom from tumor progression, serviceable hearing preservation (SHP), and neurological function (tinnitus, vestibulopathy, House-Brackmann grade, and trigeminal nerve function) were assessed for both groups. RESULTS The observation and SRS groups each comprised 51 matched patients (median age 68 years for both). Ipsilateral serviceable hearing was observed at presentation for 35 patients in each group. The median follow-up duration was 39 months in the observation group versus 27 months in the SRS group (p = 0.5). Tumor progression was significantly lower with SRS than with observation (2% vs 52.9%, p < 0.001). The rate of 5-year freedom from tumor progression was 100% in the SRS group versus 43% (95% CI 29%–64%) in the observation group. The rate of 10-year freedom from tumor progression was 90% (95% CI 73%–100%) in the SRS group versus 20% (95% CI 8.5%–49%) in the observation group. At the last follow-up, hearing loss occurred in 42.9% of the observation group and 51.4% of those who underwent SRS (p = 0.5). The 3-year SHP rate was 68% (95% CI 53%–88%) versus 65% (95% CI 49%–85%) (p = 0.8), and the 5-year SHP rate was 53% in both groups (95% CI 36%–78% in the observation group and 95% CI 35%–79% in the SRS group, p = 0.8). The composite endpoint of tumor progression and/or worsened neurological outcome, including hearing loss, tinnitus, vestibulopathy, facial nerve dysfunction (House-Brackmann grade), or trigeminal dysfunction, demonstrated a significantly lower rate in the SRS group (17.6%) compared with the observation group (66.7%) (p < 0.001). CONCLUSIONS SRS in older patients for management of Koos grade I or II VS resulted in significantly superior rates of freedom from tumor progression, comparable hearing preservation rates, and significantly higher rates of favorable overall radiographic and neurological outcomes than observation alone. Compared with observation, SRS might be the preferred management option in this patient population.
Impact of repeated ovulation induction and superovulation on ovarian reserve and early embryo development in obese and PCOS-like mouse models
Kunhiraman, Jyolsna Ponnaratta, Dcunha, Reyon, Madhvacharya, Vanishree Vasave , R, Vani Lakshmi, Venkatraman, Ganesh, Shah, Nidhi Rajesh, Kumar, Anujith , Adiga, Satish Kumar , Kalthur, Guruprasad , Kalthur, Guruprasad , Adiga, Satish Kumar , R, Vani Lakshmi , Venkatraman, Ganesh , Kannan, Nagarajan

Mayo Clinic

Reproduction, Fertility and Development | May 14, 2026 | Volume: 38 | Issue: 8 | Pages: No page available

10.1071/rd26037 | PMID 42128672 Get It

Context Women with obesity or polycystic ovary syndrome (PCOS) often require repeated ovulation induction (OI) due to ovulatory dysfunction and infertility. However, the cumulative effects of repeated stimulation on ovarian function and embryo development remain poorly understood. Aims The present study aimed to understand the consequences of repeated OI and/or repeated superovulation (SO) on preimplantation embryonic development in obese (high-fat diet-induced) and PCOS (high-fat diet and dehydroepiandrosterone-induced) mouse models. Methods Control (without any metabolic disorder), obese, and PCOS mice were divided into three experimental groups. The mice in one round of superovulation (SO1) were injected with 5 IU intraperitoneal (i.p.) injection of pregnant mare serum gonadotropin, followed by 10 IU of human chorionic gonadotropin 48 h later. In the repeated superovulation (SO3) group, mice were subjected to three rounds of superovulation with a gap of 9 days between each superovulation. Mice in the OI3 + SO3 group were administered with three doses of CC (50 mg/kg body weight, i.p., gap of 9 days between each CC injection), followed by three rounds of superovulation. Key results Both single and three rounds of superovulation resulted in decrease in primordial follicles and a moderate increase in atretic follicles in obese and PCOS mice. Reduction in the number of ovulated oocytes, increased rate of abnormal fertilization, decrease in blastocyst rate and elevated DNA damage in blastocysts were observed in in vitro fertilization-derived embryos. Conclusions These findings demonstrate compromised embryonic development following repeated ovarian stimulation. Implications The study highlights need for mild ovarian stimulation strategies in metabolically compromised patients undergoing infertility treatments.
Novel synbiotic yoghurt restores ketogenic diet responsiveness and reduces Alzheimer’s disease pathology in 3xTg-AD mice
James, Adewale, Miller, Brandi, Mishra, Sidharth, Prajapati, Santosh, Chaudhari, Diptaraj, Maleki, Sima , Kumar, Vivek, Adil, Noorul Ain, Omo-erigbe, Christabel, Tangudu, Divyani, Goltz, Dayna, Neth, Bryan, Craft, Suzanne, Jain, Shalini, Yadav, Hariom, Neth, Bryan J. , Mishra, Sidharth P. , Neth, Byran J. , Miller, Brandi C. , Chaudhari, Diptaraj , Goltz, Dayna , Craft, Suzanne , Jain, Shalini, Yadav, Hariom

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2297683 Get It

Alzheimer’s disease (AD) is characterized by profound metabolic dysfunction and disturbances in gut–brain axis signaling. Ketogenic diet (KD) has demonstrated metabolic and cognitive benefits in both preclinical and clinical studies. However, factors that determine individual responsiveness or non-responsiveness to KD interventions remain poorly understood. Emerging evidence suggests that gut microbiome composition plays a critical role in modulating these factors. This study examined how KD responsiveness, determined by fecal microbiota transplantation (FMT) derived from human KD responders (RES) or non-responders (nRES)- influences cognition, gut barrier function, neuroinflammation, and microbial structure in 3xTg-AD mice. We further evaluated whether supplementing KD with a novel Synbiotic Yogurt (SY) formulated by our team could augment or restore responsiveness. We hypothesized that RES microbiota would confer superior KD-driven benefits and that KD-SY would synergistically improve metabolic and neurobiological outcomes, particularly among nRES recipients. Adult 3xTg-AD mice were antibiotic-cleansed and randomized to receive Control-, RES-, or nRES – FMT, while maintained on KD for four weeks. A second cohort received KD supplemented with SY or non-fat milk along with RES- or nRES-FMT. Behavioral tests, gut permeability assay, serum inflammatory markers, brain amyloid beta (Aβ), intestinal morphology, gene expression, and 16S rRNA microbial profiling were measured. RES-FMT recipients showed early improvements in spatial memory (Y-maze and novel object recognition) and consistently lower Aβ accumulation in cortex and hippocampus. They also showed higher synaptophysin and IL-10 expression. In contrast, nRES-FMT mice exhibited distinct microbiome clustering, lower microbial diversity, enrichment of Proteobacteria, and impaired gut barrier function relative to RES-FMT recipients. Functionally, specific taxa like Enterococcus, Enterobacter, and Paenibacillus were associated with greater vulnerability to AD-related pathology, while Akkermansia, Bifidobacterium, and Muribaculum were linked with lower vulnerability. SY supplementation improved metabolic and gut barrier indices across groups characterized by increased circulating ketone levels, lowered fasting glucose and glucose-ketone index, and decreased gut permeability. nRES-SY mice showed the strongest gains in recognition memory and reductions in brain Aβ1–42 burden. SY increased expression of barrier- and inflammation-modulating genes, including occludin, APLP2, and IL-10. Microbiome analysis demonstrated higher microbial diversity and enrichment of beneficial genera such as Paralactobacillus, Eubacterium, and Muribaculum. These findings show that KD responsiveness is strongly determined by gut microbiota composition and that SY supplementation can enhance or rescue metabolic, cognitive, and microbial outcomes, particularly in nonresponders. This supports a precision-microbiome strategy combining metabolic and Synbiotic interventions to improve gut–brain axis function in AD. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Applications of Artificial Intelligence in Urodynamic Data Interpretation: A Narrative Review
Pourghazi, Farzad , Chaudhary, Pradeep Kumar , Fatemi, Mostafa , Linder, Brian J , Alizad, Azra , Fatemi, Mostafa , Linder, Brian J. , Alizad, Azra

Mayo Clinic

Neurourology and Urodynamics | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/nau.70308 | PMID 42117523 Get It

ABSTRACT Background Interpretation of urodynamic studies (UDS) is central to diagnosing lower urinary tract dysfunction, but it is often complex, time‐consuming, and subject to interobserver variability. Recent advances in artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), have enabled automated analysis of multichannel pressure–flow data and may improve objectivity and efficiency in UDS interpretation. Objective To critically review current applications of ML and DL for interpretation of multichannel UDS data and to evaluate their performance, clinical targets, and limitations. Methods A literature search of PubMed, Scopus, and Web of Science was performed through September 2, 2025, without language or date restrictions. A narrative review was conducted of peer‐reviewed studies applying ML or DL techniques to invasive UDS signals, including vesical, abdominal, and detrusor pressures as well as urinary flow. Studies limited to uroflowmetry or non‐UDS inputs were excluded. Model design, input features, validation strategies, and clinical outcomes were systematically assessed. Results A total of 12 studies met inclusion criteria. AI models were applied to a range of UDS tasks, including detection of detrusor overactivity, classification of bladder outlet obstruction and detrusor underactivity, multi‐feature UDS pattern recognition, severity grading, and real‐time event detection. Reported diagnostic performance was generally high, with many models achieving accuracies or AUCs between 80% and 95% for primary outcomes. However, study designs were heterogeneous, most datasets were retrospective and single‐center, and external validation was limited. Conclusions ML and DL approaches can extract clinically meaningful information from multichannel UDS recordings and demonstrate strong technical performance across several diagnostic tasks. However, variability in methodology, limited generalizability, and lack of prospective validation currently limit clinical adoption. AI‐based UDS interpretation remains an emerging research area requiring standardized data, robust validation, and integration with clinical workflows.
Making the Most of a Transplant ID Conference: A Practical Guide for Trainees and Early‐Career Faculty
Gorsline, Chelsea A. , Kumar, Rebecca N. , McCulloch, Denise J , Limaye, Ajit P, Abidi, Maheen Z. , Limaye, A.P., Harris, Courtney E.

Mayo Clinic

Transplant Infectious Disease | May 12, 2026 | Volume: 28 | Issue: 3 | Pages: No page available

10.1111/tid.70228 | PMID 42101917 Get It

ABSTRACT Attending conferences is a foundational component of professional growth in transplant infectious diseases (TIDs), yet trainees and early‐career faculty often face an overwhelming array of meeting options and limited guidance on how to maximize the experience. This report outlines practical strategies for selecting the most impactful conferences, preparing effectively, engaging with poster sessions, cultivating meaningful professional connections, and incorporating rest and reflection into conference travel. Unlike previous discussions hosted by the TID Early Career Network (TxIDECN), which typically occurred over social media, this was a live expert panel with audience participation at the 2025 Fred Hutch Symposium on Infectious Diseases in the Immunocompromised Host on May 13, 2025, in Seattle, Washington. Here, we summarize that discussion with actionable tools to navigate conferences intentionally and translate these experiences into sustained academic and career development for emerging TID professionals. image
Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From JCO Global Oncology
Nguyễn, Long Thành , Hoyek, Celine , Magliano, Carlos, Mano, Max S., Prabhash, Kumar, Moraes, Fabio Ynoe , Loon, Katherine Van , Sonbol, Mohamad Bassam , Van Loon, Katherine , Kapoor, Akhil , Magliano, Carlos Alberto da Silva , Mano, Max S.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 11, 2026 | Volume: 46 | Issue: 3 | Pages: No page available

10.1200/edbk-26-528840 | PMID 42114030 Get It

By 2045, more than three quarters of global cancer deaths are projected to occur in low- and middle-income countries (LMICs); however, the global availability of cancer care remains constrained by high costs and inequitable access. Value-based frameworks that integrate clinical benefit with affordability, feasibility, and equity are essential to better guide research prioritization, resource allocation, and regulatory policies in LMICs. A key component of a value-based approach is the generation of high-quality, locally relevant data to support evidence-based implementation of cancer prevention and control strategies. Herein, we provide three contemporary examples from JCO Global Oncology which demonstrate how economic evaluation in cancer research can address locally relevant, health system–specific questions.
Predictors of renal response in AL amyloidosis following anti‐plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype
Rees, Matthew J., Yohannan, Binoy, Geyer, Susan M. , Atallah‐Yunes, Suheil Albert , Toumeh, Nadia , Gertz, MA, Dispenzieri, Angela, Leung, Nelson , Hayman, Suzanne, Buadi, Francis, Dingli, David, Warsame, Rahma, Kapoor, Prashant , Kourelis, Taxiarchis, Gonsalves, Wilson, Kumar, Shaji, Gertz, Morie A. , Geyer, Susan , Gertz, Morie A , Cook, Joselle M , Rajkumar, S Vincent , Muchtar, E , Leung, Nelson , Atallah-Yunes, Albert , Rees, Matthew J. , Yohannan, Binoy, Dispenzieri, Angela , Hayman, S., Buadi, Francis K. , Cook, Joselle , Dingli, David , Warsame, Rahma , Binder, Moritz , Kourelis, Taxiarchis , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Kumar, Shaji , Muchtar, Eli

Mayo Clinic

British Journal of Haematology | May 11, 2026 | Volume: 209 | Issue: 1 | Pages: 149-159

10.1111/bjh.70542 | PMID 42108212 Get It

Summary Renal response (RenR) in light‐chain (AL) amyloidosis is associated with a lower risk of end‐stage kidney disease and improved survival. However, substantial variation exists in the time to and depth of RenR. We investigated variables associated with RenR in a retrospective study of newly diagnosed AL amyloidosis patients ( n = 350) assessable for RenR between 2010 and 2022. RenRs were recorded at 6, 12 and 24 months and best response. Deep RenR was defined as a ≥renal very good partial response (RenVGPR, >60% reduction in 24‐h proteinuria or ≤200 mg). Logistic regression and competing risk methods were used to examine variables associated with RenR. The median age was 64 years, and median follow‐up was 5.5 years. On multivariable logistic regression, obtaining ≥HemVGPR within 6 months, kappa isotype, high baseline difference between involved and uninvolved free light chains (dFLC ≥40 mg/dL), renal stage and autologous haematopoietic stem cell transplant (AHSCT) were significantly associated with deep RenR. Cumulative incidence rates for deep RenR, treating death or renal progression as a competing event, demonstrated that early HemR, first‐line AHSCT, lower renal stage and dFLC ≥40 mg/dL significantly increased the likelihood of deep RenR. Specific clonal plasma cell features, namely light‐chain isotype and baseline dFLC levels, independently influence the timing and depth of RenRs in AL amyloidosis following treatment, in addition to renal stage and HemR.
0187 Investigating the Influence of Daily Sleep Disturbances and Biopsychosocial Influences on Daily Pain in Chronic Pain Patients
Holland, Britani, Robinson, Michael, Staud, Roland, Craggs, Jason, Curtis, Ashley, McGovney, Kevin, Davenport, Mattina, Berry, J.L. , Richardson, Marlee, Sahota, Pradeep, Chokkalingam, Siva, McCrae, Christina, Moore, Matthew R. , Robinson, Michael, Staud, Roland M. , Craggs, Jason G. , McGovney, Kevin , Davenport, Mattina , Berry, Jasmine, Sahota, Pradeep Kumar , McCrae, Christina S.

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A82-A82

10.1093/sleep/zsag091.0187 Get It

Abstract Introduction Daily fluctuations in sleep disturbances have been shown to shape pain experiences among individuals with chronic pain. Additional biobehavioral factors, such as abuse history, depression, current and long-term anxiety, opioid use, physical functioning, and fatigue, may also affect daily pain outcomes. Yet the extent to which these factors collectively contribute to daily pain intensity and unpleasantness remains insufficiently understood. Methods Using baseline data from the SPINII randomized controlled trial (R01NR017168; McCrae, PI), women with insomnia and fibromyalgia (N = 294, x- age = 40) completed 14 days of sleep diaries assessing sleep onset latency (SOL), wake after sleep onset (WASO), total sleep time (TST), and pain intensity and unpleasantness (0–100). Additional predictors included abuse history, Beck Depression Inventory (BDI), State–Trait Anxiety Inventory (STAI), and PROMIS-57 physical functioning and social functioning. Linear mixed models examined the effects of sleep and related factors on daily pain. Results Significant predictors of pain intensity included higher between-person SOL (b = 0.08, p &lt; .001) and WASO (b = 0.08, p &lt; .001), lower between-person TST (b = -0.10, p &lt; .001), lower within-person TST (b = −0.03, p &lt; .001), opioid use (b = 2.84, p = .029), poorer physical functioning (b = −0.35, p = .008), and higher depression scores (b = 0.20, p = .046). Pain unpleasantness showed nearly identical patterns, with only physical functioning becoming non-significant. Random intercepts and residual variance values were significant in both models (p &lt; .001), indicating within- and between-person variation in pain. ICCs of .80-.85 revealed that the majority of variance was between-person, while non-significant autocorrelations (p &gt; .05) indicated minimal day-to-day carryover effects beyond stable individual differences. Conclusion Overall sleep quality and emotional health shape pain experience more strongly than daily fluctuations. Although TST offers some next-day relief, chronic contributors are more relevant to daily pain. Effects were largely consistent; between- and within-person TST showed strong effects, and depression had a slightly larger effect on pain unpleasantness than pain sensitivity, reinforcing a multidimensional biopsychosocial pain process. These findings highlight the need for integrated interventions that strengthen sleep, emotional well-being, and physical functioning. Support (if any) NIDA
0425 When the Day Starts with An Ache: Morning Headaches and Sleep Patterns in Women with Insomnia and Pain Complaints
Richardson, Marlee, Stearns, Melanie, Curtis, Ashley, Robinson, Michael, Staud, Roland, Craggs, Jason, Davenport, Mattina, Sahota, Pradeep, Chokkalingam, Siva, Berry, J.L. , McCrae, Christina, Stearns, Melanie , Robinson, Michael, Staud, Roland M. , Craggs, Jason G. , Davenport, Mattina , Sahota, Pradeep Kumar , Berry, Jasmine, McCrae, Christina S.

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A189-A189

10.1093/sleep/zsag091.0425 Get It

Abstract Introduction Chronic and episodic headaches have a strong bidirectional relationship with insomnia and poor sleep outcomes. AM (morning) headaches are common among chronic pain populations, but additional research is needed to understand their pain experiences and potentially inform targeted interventions. Herein, we investigated whether presence of AM headaches is associated with differences in diary-based sleep parameters and pain ratings in women with pain and sleep complaints. We hypothesize individuals with AM headaches will have more sleep disturbances and fatigue as well as greater pain intensity and unpleasantness. Methods Women (N=293, Mage=39.59, SD 12.65, 65% with morning headaches) reporting insomnia and pain complaints (65% also reporting morning headaches) were recruited in mid-Missouri for an RCT (R01NR017168, ClinicalTrials.gov Identifier: NCT03744156). During baseline assessment, participants completed 2 weeks of daily electronic diaries and reported AM headache presence (Y/N). Independent samples t-tests (SPSS) evaluated differences in sleep parameters and pain ratings in those with and without AM headaches. Participants reporting diagnosed sleep apnea were excluded. Results Morning fatigue was higher among individuals with AM headaches (M=54.72+/-18.25) than those without (M=50.02+/-19.12), t(291)=-2.07, p=.04. Pain intensity was greater in the AM headache group in the morning (M=47.65+/-19.73 vs. M=42.52+/-21.91), t(291)=-2.04, p=.042, and evening, (M=49.62+/-19.10 vs. M=44.23+/-20.66), t(283)=-2.21, p=.028. Evening pain unpleasantness was also rated as higher among those with AM headaches (M=45.90+/-19.55) compared to those without (M=40.82+/-22.52), t(283)=-1.99, p=.048, but morning pain unpleasantness ratings only trended towards significance. Conclusion AM headaches can present as a chronic condition or as a symptom of other sleep disorders. Individuals with AM headaches had minimal sleep differences overall, but morning fatigue, pain intensity (AM and PM), and evening pain unpleasantness ratings were all significantly greater in those with AM headaches. Undiagnosed sleep disorders other than insomnia (i.e., obstructive sleep apnea) or other health concerns, like increased intracranial pressure, may have contributed to pain-related findings. Considering the high prevalence of COMISA in chronic pain populations, further investigation should examine its impact on sleep and headache severity. Support (if any) National Institute of Nursing Research (NR017168; Clinical trial: NCT03744156; PI: McCrae).